[Update on antithrombotic treatments in arterial diseases].
In most cases, arterial diseases are characterized by atherothrombosis causing organ or limb ischemia. Antithrombotic agents are a cornerstone in the therapeutic management of this pathology. Present approaches include anticoagulants and four types of antiplatelet drugs: aspirin, thienopyridines, dipyridamole and the anti-GPIIbIIIa molecules. Several questions are still pending, in particular concerning treatment tailoring according to clinical presentation and the duration of the antiplatelet treatment. This review focuses on the indications of the currently available antithrombotic agents in arterial diseases of atherothrombotic origin.
Fontana
P
P
Service d'angiologie et d'hémostase, Département de médecine interne, Faculté de médecine et HUG, Genève. pierre.fontana@medecine.unige.ch
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy*; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C446540:thienopyridine; D014443:Tyrosine; D004176:Dipyridamole; D000077466:Tirofiban; D000077542:Eptifibatide; D001241:Aspirin; D000077284:Abciximab